Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.28 -0.2%	$5.95	$4.35 ▼ $12.38	$315.70M	0.43	209,378 shs	1.31 million shs
ITOS iTeos Therapeutics	$9.95 -0.7%	$8.70	$4.80 ▼ $18.13	$380.79M	1.51	684,286 shs	1.32 million shs
LGST Semper Paratus Acquisition	$4.51	$4.52	$4.08 ▼ $12.03	$71.35M	-0.08	30,930 shs	12,596 shs
SLDB Solid Biosciences	$4.72 -1.9%	$3.68	$2.41 ▼ $10.37	$365.85M	2.22	1.18 million shs	7.02 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	+3.97%	+7.53%	+7.17%	-16.93%
ITOS iTeos Therapeutics	0.00%	-0.10%	-0.30%	+66.67%	-32.95%
LGST Semper Paratus Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
SLDB Solid Biosciences	0.00%	-1.46%	+47.50%	+27.57%	-16.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.6025 of 5 stars	3.6	1.0	0.0	0.0	3.2	3.3	0.0
ITOS iTeos Therapeutics	3.2038 of 5 stars	4.1	2.0	0.0	0.0	1.6	3.3	0.6
LGST Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	3.4424 of 5 stars	4.6	2.0	0.0	0.0	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.00	250.32% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	59.37% Upside
LGST Semper Paratus Acquisition	0.00	N/A	N/A	N/A
SLDB Solid Biosciences	3.17	Buy	$15.10	219.92% Upside

Current Analyst Ratings Breakdown

Latest LGST, ITOS, SLDB, and AURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
ITOS iTeos Therapeutics	$35M	10.88	N/A	N/A	$16.16 per share	0.62
LGST Semper Paratus Acquisition	N/A	N/A	$0.33 per share	13.74	($1.10) per share	N/A
SLDB Solid Biosciences	$8.09M	45.22	N/A	N/A	$3.43 per share	1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
LGST Semper Paratus Acquisition	$4.41M	N/A	0.00	∞	N/A	N/A	-21.83%	3.10%	N/A
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest LGST, ITOS, SLDB, and AURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
LGST Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	11.06	11.06
ITOS iTeos Therapeutics	N/A	14.13	14.13
LGST Semper Paratus Acquisition	N/A	0.22	0.22
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
ITOS iTeos Therapeutics	97.16%
LGST Semper Paratus Acquisition	N/A
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
ITOS iTeos Therapeutics	12.50%
LGST Semper Paratus Acquisition	56.60%
SLDB Solid Biosciences	13.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
LGST Semper Paratus Acquisition	2,021	15.82 million	6.86 million	Not Optionable
SLDB Solid Biosciences	100	77.51 million	66.95 million	Optionable

LGST, ITOS, SLDB, and AURA Headlines

Recent News About These Companies

Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at Citigroup

June 29 at 2:07 AM | americanbankingnews.com

SLDB - Solid Biosciences Inc Valuation - Morningstar

June 27 at 7:32 PM | morningstar.comM

Solid Biosciences (NASDAQ:SLDB) Raised to "Strong-Buy" at Citigroup

June 27 at 5:55 AM | marketbeat.com

Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation

June 26, 2025 | msn.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives $14.90 Consensus PT from Analysts

June 24, 2025 | americanbankingnews.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

...

June 18, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC Wainwright

June 17, 2025 | marketbeat.com

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13, 2025 | tipranks.com

Brokers Offer Predictions for SLDB FY2026 Earnings

June 10, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Solid Biosciences' (SLDB) "Market Outperform" Rating Reiterated at JMP Securities

June 6, 2025 | marketbeat.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update

June 3, 2025 | marketbeat.com

Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

June 1, 2025 | marketbeat.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

When Might Solid Biosciences Run Out Of Money?

May 17, 2025 | finance.yahoo.com

Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 16, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

LGST, ITOS, SLDB, and AURA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.28 -0.01 (-0.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.79 +0.51 (+8.12%)

As of 09:02 AM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

iTeos Therapeutics NASDAQ:ITOS

$9.95 -0.07 (-0.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.98 +0.03 (+0.25%)

As of 08:34 AM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Semper Paratus Acquisition NASDAQ:LGST

Semper Paratus Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to acquire companies operating in the transportation, supply chain, and logistics industries. Semper Paratus Acquisition Corporation was incorporated in 2021 and is based in New York, New York. Semper Paratus Acquisition Corporation operates as a subsidiary of Ssvk Associates, Llc.

Solid Biosciences NASDAQ:SLDB

$4.72 -0.09 (-1.87%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.88 +0.16 (+3.39%)

As of 09:01 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time